Research Article| Volume 31, ISSUE 2, P436-445, February 2009

Download started.


Estimates of pediatric medication use in the United States: Current abilities and limitations

  • Tamar Lasky
    Address correspondence to: Tamar Lasky, PhD, Associate Professor, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 144 Fogarty Hall, Kingston, RI 02881.
    Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Background: Resources are available for measuring adult medication use, but similar resources have not been fully developed for measuring pediatric use. Policy decisions require an understanding of the population affected, the number of children, their ages, sex, geographic distribution, race and ethnicity, and insurance status, as well as trends over time.
      Objective: In this article, databases providing information about prescription drugs used in the United States are reviewed with respect to pediatric populations.
      Methods: A series of searches were conducted in MEDLINE using these terms: frequency, prevalence, drug utilization, children, pediatric, drug usage, medications, and prescriptions. Authors of selected articles were interviewed to identify salient issues in the measurement of pediatric medication use. Preliminary analysis of several databases followed within the context of government implementation of the Best Pharmaceuticals for Children Act. This was followed by further MEDLINE searches and synthesis of the literature.
      Results: Databases with information about pediatric population medication use included 7 with outpatient data and 4 with inpatient data. Outpatient data were available from government and private sources, but inpatient data were available from private sources only. Three of the government and 1 of the private databases with outpatient data had sample sizes of several thousand, too small to allow analysis of frequency trends in pediatric populations or subpopulations, in which many drugs are used by fewer than 0.01% of patients.
      Conclusions: Sample size needs are greater when measuring pediatric medication use because the overall level of use is lower among children than adults. Databases resulting from hospital quality efforts, conglomeration of pharmacy benefit records, and standardization of state Medicaid records offer opportunities to describe prescription medication use in samples of several hundred thousand to several million children but will require dedicated resources.

      Key words:

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Meadows M
        Drug research and children.
        FDA Consum. 2003; 37: 12-17
        • Steinbrook R
        Testing medications in children.
        N Engl J Med. 2002; 347: 1462-1470
        • Chesney RW
        • Christensen ML
        Changing requirements for evaluation of pharmacologic agents.
        Pediatrics. 2004; 113: 1128-1132
        • Gorman RL
        The march toward rational therapeutics in children.
        Pediatr Infect Dis J. 2003; 22: 1119-1123
        • Kauffman RE
        Status of drug approval processes and regulation of medications for children.
        Curr Opin Pediatr. 1995; 7: 195-198
        • Roberts R
        • Rodriguez W
        • Murphy D
        • Crescenzi T
        Pediatric drug labeling: Improving the safety and efficacy of pediatric therapies.
        JAMA. 2003; 290: 905-911
      1. Pediatric pharmaceutical usage—request for comment.
        Federal Register. 2003; 68: 54912
        • Raofi S
        • Schappert SM
        Medication therapy in ambulatory medical care: United States, 2003–04.
        Vital Health Stat. 2006; 13: 1-40
        • Ferris TG
        • Kuhlthau K
        • Ausiello J
        • et al.
        Are minority children the last to benefit from a new technology? Technology diffusion and inhaled corticosteroids for asthma.
        Med Care. 2006; 44: 81-86
        • Morton KM
        • Willsie SK
        • Lynch JK
        Outpatient prescribing practices for nonapproved drugs in children.
        J Am Osteopath Assoc. 2005; 105: 24
        • Robison LM
        • Sclar DA
        • Skaer TL
        • Galin RS
        Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995–99.
        Int Clin Psychopharmacol. 2004; 19: 17-22
        • Stojanovski SD
        • Rasu RS
        • Balkrishnan R
        • Nahata MC
        Trends in medication prescribing for pediatric sleep difficulties in US outpatient settings.
        Sleep. 2007; 30: 1013-1017
        • Stagnitti MN
        The Top Five Outpatient Prescription Drugs Ranked by Total Expense for Children, Adults, and the Elderly, 2004.
        Statistical Brief 180. July 2007 (Accessed)
      2. National Health and Nutrition Examination Survey. Patterns of Prescription Drug Use in the United States, 1988–94.

      3. (Accessed)
      4. Frequency of Medication Usage in the Pediatric Population: Detailed Report, Part 1 of 2. National Institute of Child Health and Human Development, Rockville, MD2005 (Contract no. GS-23F-8144H. Task order no. HHSN275200403388C)
        • Bosco LA
        • Gerstman BB
        • Tomita DK
        Variations in the use of medication for the treatment of childhood asthma in the Michigan Medicaid population, 1980 to 1986.
        Chest. 1993; 104: 1727-1732
        • Fox MH
        • Foster CH
        • Zito JM
        Building pharmacoepidemiological capacity to monitor psychotropic drug use among children enrolled in Medicaid.
        Am J Med Qual. 2000; 15: 126-136
        • Zito JM
        • Safer DJ
        • dosReis S
        • et al.
        Trends in the prescribing of psychotropic medications to preschoolers.
        JAMA. 2000; 283: 1025-1030
        • Zito JM
        • Safer DJ
        • DosReis S
        • et al.
        Psychotropic practice patterns for youth: A 10-year perspective.
        Arch Pediatr Adolesc Med. 2003; 157: 17-25
        • Zito JM
        • Safer DJ
        • dosReis S
        • et al.
        Methylphenidate patterns among Medicaid youths.
        Psychopharmacol Bull. 1997; 33: 143-147
        • Zito JM
        • Safer DJ
        • dosReis S
        • Riddle MA
        Racial disparity in psychotropic medications prescribed for youths with Medicaid insurance in Maryland.
        J Am Acad Child Adolesc Psychiatry. 1998; 37: 179-184
        • Wenzlow AT
        • Finkelstein D
        • Le Cook B
        • et al.
        The Medicaid Analytic eXtract Chartbook. Centers for Medicare & Medicaid Services, Baltimore, MD2007 (Accessed)
        • Rodriguez EM
        • Staffa JA
        • Graham DJ
        The role of databases in drug postmarketing surveillance.
        Pharmacoepidemiol Drug Saf. 2001; 10: 407-410
      5. Transcript. Pediatric Subcommittee of the Anti-Infective Drugs Advisory, June 11, 2002.

      6. (Accessed)
        • Wysowski DK
        • Armstrong G
        • Governale L
        Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001.
        Diabetes Care. 2003; 26: 1852-1855
        • Scott L
        APS moves ahead on Express Scripts deal.
        Mod Healthc. 1996; 26: 58
        • Taulbee P
        AmHs, Express Scripts plan partnership to build joint formularies.
        Healthc Syst Strategy Rep. 1995; 12: 9
        • Fairman KA
        • Teitelbaum F
        • Drevets WC
        • et al.
        Course of antidepressant treatment with tricyclic versus selective serotonin reuptake inhibitor agents: A comparison in managed care and fee-for-service environments.
        Am J Manag Care. 1997; 3: 453-465
        • Motheral BR
        • Fairman KA
        The use of claims databases for outcomes research: Rationale, challenges, and strategies.
        Clin Ther. 1997; 19: 346-366
        • Cox ER
        • Motheral BR
        • Henderson RR
        • Mager D
        Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: Results from a commercially insured US sample.
        Pediatrics. 2003; 111: 237-243
        • Roe CM
        • McNamara AM
        • Motheral BR
        Gender- and age-related prescription drug use patterns.
        Ann Pharmacother. 2002; 36: 30-39
      7. Frequency of Medication Usage in the Pediatric Population: Detailed Report, Part 2 of 2. National Institute of Child Health and Human Development, Rockville, MD2005 (Contract no. GS-23F-8144H. Task order no. HHSN275200403388C)
        • Lasky T
        BPCA: The Annual Drug Prioritization Process, Presented at: 40th Annual Meeting of the Drug Information AssociationJune 16, 2004 (Washington, DC)
        • Zito JIM
        • Safer DJ
        • Valluri S
        • et al.
        Psychotherapeutic medication prevalence in Medicaid-insured preschoolers.
        J Child Adolesc Psychopharmacol. 2007; 17: 195-203
        • Allen-Ramey FC
        • Samet JM
        • Rand CS
        • Joseph CL
        Trends in use of inhaled corticosteroids for asthma management: 1994–1998.
        Ann Epidemiol. 2004; 14: 161-167
        • Koran LM
        • Leventhal JL
        • Fireman B
        • Jacobson A
        Pharmacotherapy of obsessive-compulsive disorder in a health maintenance organization.
        Am J Health Syst Pharm. 2000; 57: 1972-1978
        • McPhillips HA
        • Stille CJ
        • Smith D
        • et al.
        Potential medication dosing errors in outpatient pediatrics.
        J Pediatr. 2005; 147: 761-767
        • Shah SS
        • Hall M
        • Goodman DM
        • et al.
        Off-label drug use in hospitalized children [published correction appears in Arch Pediatr Adolesc Med. 2007;161:655].
        Arch Pediatr Adolesc Med. 2007; 161: 282-290
      8. Healthcare Cost and Utilization Project (HCUP).
        in: HCUP Kids' Inpatient Database (KID). Agency for Healthcare Research and Quality, Rockville, MD2003
        • Clark RH
        • Bloom BT
        • Spitzer AR
        • Gerstmann DR
        Reported medication use in the neonatal intensive care unit: Data from a large national data set.
        Pediatrics. 2006; 117: 1979-1987
        • Du W
        • Warrier I
        • Tutag Lehr V
        • et al.
        Changing patterns of drug utilization in a neonatal intensive care population.
        Am J Perinatol. 2006; 23: 279-285
        • Gortner L
        • Bernsau U
        • Brand M
        • et al.
        Drug utilization in very premature infants in neonatal intensive care units.
        Dev Pharmacol Ther. 1991; 17: 167-171
        • Kahn DJ
        • Richardson DK
        • Gray JE
        • et al.
        Variation among neonatal intensive care units in narcotic admin istration.
        Arch Pediatr Adolesc Med. 1998; 152: 844-851
        • AI-Aweel I
        • Pursley DM
        • Rubin LP
        • et al.
        Variations in prevalence of hypotension, hypertension, and vasopressor use in NICUs.
        J Perinatol. 2001; 21: 272-278
        • Lawless S
        • James R
        • Hildebrand I
        • Frank G
        The Prevalence of Inpatient Pediatrics Prescribed and Administered Medications. National Institute of Child Health and Human Development, Rockville, MD2005 (Purchase Order # G/L-10148070)
      9. US Dept of Health and Human Services Food and Drug Administration. Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products.

      10. (Accessed)
      11. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of “Pediatric Use” Subsection in the Labeling; Final Rule. 21 CFR §201.

      12. (Accessed)
      13. US Dept of Health and Human Services, Office for Human Research Protections (OHRP). Special Protections for Children as Research Subjects.

      14. http://www.hhs.govohrp/children
        Date: January 20, 2009
      15. Guidance for Industry, E11: Clinical Investigation of Medicinal Products in the Pediatric Population. US Dept of Health and Human Services, December 2000.

      16. (Accessed)
        • Ward RM
        • Benitz WE
        • Benjamin DK
        • et al.
        Criteria supporting the study of drugs in the newborn.
        Clin Ther. 2006; 28: 1385-1398
        • AAP Committee on Coding and Nomenclature
        CPT 2007 includes new, revised pediatric codes.
        AAP News. 2007; 28: 30
        • Giacoia GP
        • Birenbaum DL
        • Sachs HC
        • Mattison DR
        The newborn drug development initiative.
        Pediatrics. 2006; 117: S1-S8
        • Giacoia GP
        • Mattison DR
        Newborns and drug studies: The NICHD/FDA newborn drug development initiative.
        Clin Ther. 2005; 27: 796-813
        • Warrier I
        • Du W
        • Natarajan G
        • et al.
        Patterns of drug utilization in a neonatal intensive care unit.
        J Clin Pharmacol. 2006; 46: 449-455
        • Zito JM
        • Safer DJ
        • dosReis S
        • et al.
        Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.
        Arch Pediatr Adolesc Med. 1999; 153: 1257-1263
        • Bhatara V
        • Feil M
        • Hoagwood K
        • et al.
        National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge.
        J Atten Disord. 2004; 7: 217-226
        • Olfson M
        • Blanco C
        • Liu L
        • et al.
        National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
        Arch Gen Psychiatry. 2006; 63: 679-685
        • Cox ER
        • Halloran DR
        • Homan SM
        • et al.
        2002–2005 Trends in the prevalence of obesity-related chronic medication use in children, Presented at: American Public Health Association 135th Annual MeetingNovember 3–7, 2007 (Washington, DC)
        • Mainous III, AG
        • Hueston WJ
        • Clark JR
        Antibiotics and upper respiratory infection: Do some folks think there is a cure for the common cold.
        J Fam Pract. 1996; 42: 357-361
        • Rushton JL
        • Whitmire JT
        Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998.
        Arch Pediatr Adolesc Med. 2001; 155: 560-565
      17. Meyer J. Age: 2000. Census 2000 Brief.

      18. (Accessed)
      19. MEPS-HC Unweighted Sample Sizes by Policy Relevant Groups for 2005.

      20. (Accessed)
      21. Unweighted Response Rates for NHANES 2003–2004 by Gender and Age.

      22. (Accessed)
      23. Agency for Healthcare Research and Quality. Prescribed Drug Estimates: 2005.

      24. (Accessed)
        • Stagnitti MN
        Trends in Outpatient Prescription Drug Utilization and Expenditures, 1997 and 2004.
        Statistical Brief 168. April 2007 (Accessed)